Altered glycosylation in prostate cancer.

Prostate cancer is annually the most common newly diagnosed cancer in men. The prostate functions as a major secretory gland for the production of glycoproteins critical to sperm activation and reproduction. Prostate-specific antigen (PSA), produced by the prostate, is one of the most commonly assayed glycoproteins in blood, serving as a biomarker for early detection and progression of prostate cancer. The single site of N-glycosylation on PSA has been the target of multiple glycan characterization studies. In this review, the extensive number of studies that have characterized the changes in O-linked and N-linked glycosylations associated with prostate cancer development and progression will be summarized. This includes analysis of the glycosylation of PSA, and other prostate glycoproteins, in tissues, clinical biofluids, and cell line models. Other studies are summarized in the context of understanding the complexities of these glycan changes in order to address the many confounding questions associated with prostate cancer, as well as efforts to improve prostate cancer biomarker assays using targeted glycomic-based strategies.

[1]  J. E. Heller,et al.  Prostatic acid phosphatase: its current clinical status. , 1987, The Journal of urology.

[2]  K. Fujikawa,et al.  Characterization of the Precursor of Prostate-specific Antigen , 1997, The Journal of Biological Chemistry.

[3]  W. Grizzle,et al.  Exosomes and Cancer: A Newly Described Pathway of Immune Suppression , 2011, Clinical Cancer Research.

[4]  David Chia,et al.  Mortality results from a randomized prostate-cancer screening trial. , 2009, The New England journal of medicine.

[5]  Yuan Tian,et al.  Identification, prioritization, and evaluation of glycoproteins for aggressive prostate cancer using quantitative glycoproteomics and antibody‐based assays on tissue specimens , 2013, Proteomics.

[6]  Hui Zhang,et al.  Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer. , 2014, Glycobiology.

[7]  Udo Schumacher,et al.  Aberrant Presentation of HPA-Reactive Carbohydrates Implies Selectin-Independent Metastasis Formation in Human Prostate Cancer , 2014, Clinical Cancer Research.

[8]  B. Conley,et al.  Detection of Prostate Cancer and Predicting Progression , 2004, Clinical Cancer Research.

[9]  L. Cazares,et al.  MALDI tissue imaging: from biomarker discovery to clinical applications , 2011, Analytical and bioanalytical chemistry.

[10]  G. Bova,et al.  The glycosphingolipids of human prostate tissue. , 1988, Biochimica et biophysica acta.

[11]  W. Catalona,et al.  Clinical use of prostate specific antigen in patients with prostate cancer. , 1989, The Journal of urology.

[12]  W. Isaacs,et al.  The role of inflammation in the pathogenesis of prostate cancer. , 2004, The Journal of urology.

[13]  M. Clements,et al.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. , 2009, Journal of proteomics.

[14]  P. Scardino,et al.  Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). , 2005, Urology.

[15]  Scott R. Kronewitter,et al.  Glycomic Approach for Potential Biomarkers on Prostate Cancer: Profiling of N-Linked Glycans in Human Sera and pRNS Cell Lines , 2009, Disease markers.

[16]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[17]  Michael J. Betenbaugh,et al.  Integration of the Transcriptome and Glycome for Identification of Glycan Cell Signatures , 2013, PLoS Comput. Biol..

[18]  H. Lilja,et al.  Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. , 1999, Journal of andrology.

[19]  T. Stamey,et al.  Biological determinants of cancer progression in men with prostate cancer. , 1999, JAMA.

[20]  Y. Mechref,et al.  Glycoproteomics: Identifying the Glycosylation of Prostate Specific Antigen at Normal and High Isoelectric Points by LC–MS/MS , 2014, Journal of proteome research.

[21]  V. Magdolen,et al.  Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential regulators of activation and activity , 2014, Biological chemistry.

[22]  S. Mills,et al.  Deletion of antigens of the Lewis a/b blood group family in human prostatic carcinoma. , 1988, The American journal of pathology.

[23]  A. Gutman,et al.  AN " ACID " PHOSPHATASE OCCURRING IN THE SERUM OF PATIENTS WITH METASTASIZING CARCINOMA OF THE PROSTATE GLAND. , 1938, The Journal of clinical investigation.

[24]  Ludovic C. Gillet,et al.  Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis* , 2012, Molecular & Cellular Proteomics.

[25]  Y. Sato,et al.  Structural characteristics of the N-glycans of two isoforms of prostate-specific antigens purified from human seminal fluid. , 2001, Biochimica et biophysica acta.

[26]  D. Troyer,et al.  Increased bisecting N‐acetylglucosamine and decreased branched chain glycans of N‐linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression , 2013, Proteomics. Clinical applications.

[27]  A. Ignatchenko,et al.  In-depth proteomic analyses of direct expressed prostatic secretions. , 2010, Journal of proteome research.

[28]  D. Peehl,et al.  Determination of Carbohydrate Structure Recognized by Prostate-specific F77 Monoclonal Antibody through Expression Analysis of Glycosyltransferase Genes , 2014, The Journal of Biological Chemistry.

[29]  R. Setterquist,et al.  Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. , 2012, Biochimica et biophysica acta.

[30]  Y. Mechref,et al.  Alterations in the serum glycome due to metastatic prostate cancer. , 2007, Journal of proteome research.

[31]  W. Stoorvogel,et al.  Prostasomes: extracellular vesicles from the prostate. , 2013, Reproduction.

[32]  Kristina Schwamborn,et al.  Molecular imaging by mass spectrometry — looking beyond classical histology , 2010, Nature Reviews Cancer.

[33]  Lifang Yang,et al.  Targeted Identification of Metastasis-associated Cell-surface Sialoglycoproteins in Prostate Cancer , 2011, Molecular & Cellular Proteomics.

[34]  César L. Araujo,et al.  Transmembrane Prostatic Acid Phosphatase (TMPAP) Interacts with Snapin and Deficient Mice Develop Prostate Adenocarcinoma , 2013, PloS one.

[35]  Yue Fan,et al.  Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia. , 2011, Glycobiology.

[36]  D. Huntsman,et al.  Loss and Recovery of Mgat3 and GnT-III Mediated E-cadherin N-glycosylation Is a Mechanism Involved in Epithelial-Mesenchymal-Epithelial Transitions , 2012, PloS one.

[37]  E. Stura,et al.  Crystal structure of human prostate-specific antigen in a sandwich antibody complex. , 2011, Journal of molecular biology.

[38]  G. Kristiansen,et al.  Periostin is up-regulated in high grade and high stage prostate cancer , 2010, BMC Cancer.

[39]  W. Isaacs,et al.  Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. , 1996, Genomics.

[40]  H. Klocker,et al.  Expression of Lewis carbohydrate antigens in metastatic lesions from human prostatic carcinoma , 1998, The Prostate.

[41]  Jennifer A. Prescher,et al.  Probing mucin-type O-linked glycosylation in living animals. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Michael J Barry,et al.  Screening for prostate cancer--the controversy that refuses to die. , 2009, The New England journal of medicine.

[43]  P. Mukherjee,et al.  MUC1: a multifaceted oncoprotein with a key role in cancer progression. , 2014, Trends in molecular medicine.

[44]  R. Cummings,et al.  The bisecting GlcNAc in cell growth control and tumor progression , 2012, Glycoconjugate Journal.

[45]  R. Wolfinger,et al.  Anti‐Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer , 2013, Drug development research.

[46]  T. Kislinger,et al.  In‐depth proteomic analyses of exosomes isolated from expressed prostatic secretions in urine , 2013, Proteomics.

[47]  A. Partin,et al.  Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. , 2001, The Urologic clinics of North America.

[48]  Jennifer A. Prescher,et al.  Metabolic labeling of glycans with azido sugars for visualization and glycoproteomics. , 2006, Methods in enzymology.

[49]  R. Vessella,et al.  Human Prostate Cancer in a Clinically Relevant Xenograft Mouse Model: Identification of β(1,6)-Branched Oligosaccharides as a Marker of Tumor Progression , 2012, Clinical Cancer Research.

[50]  Stig Nordling,et al.  Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue , 2005, The Prostate.

[51]  A. Clauss,et al.  Evolution of kallikrein-related peptidases in mammals and identification of a genetic locus encoding potential regulatory inhibitors , 2006, Biological chemistry.

[52]  S. Baba,et al.  alpha1,2-Fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. , 2010, Glycobiology.

[53]  Geng Zhang,et al.  Suppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid marker , 2009, Proceedings of the National Academy of Sciences.

[54]  J. Weyler,et al.  A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck , 2009, BMC Cancer.

[55]  Irina Kalatskaya,et al.  Identification of Differentially Expressed Proteins in Direct Expressed Prostatic Secretions of Men with Organ-confined Versus Extracapsular Prostate Cancer* , 2012, Molecular & Cellular Proteomics.

[56]  W. Gerritsen.  The evolving role of immunotherapy in prostate cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  K. Pienta,et al.  Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking , 2009, Proceedings of the National Academy of Sciences.

[58]  M. Schultz,et al.  Regulation of the metastatic cell phenotype by sialylated glycans , 2012, Cancer and Metastasis Reviews.

[59]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[60]  D. Peehl,et al.  Carbohydrate Sequence of the Prostate Cancer-associated Antigen F77 Assigned by a Mucin O-Glycome Designer Array , 2014, The Journal of Biological Chemistry.

[61]  Haixu Tang,et al.  Interlaboratory Study on Differential Analysis of Protein Glycosylation by Mass Spectrometry: The ABRF Glycoprotein Research Multi-Institutional Study 2012* , 2013, Molecular & Cellular Proteomics.

[62]  Guido Jenster,et al.  Exosomes as biomarker treasure chests for prostate cancer. , 2011, European urology.

[63]  J. Dekernion,et al.  Cell surface blood group antigens in prostatic carcinoma. , 1984, American journal of clinical pathology.

[64]  H. Carter,et al.  The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. , 2006, The Journal of urology.

[65]  B. Meyer,et al.  Glycan analysis of Prostate Specific Antigen (PSA) directly from the intact glycoprotein by HR-ESI/TOF-MS. , 2014, Journal of proteome research.

[66]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[67]  Pauline M Rudd,et al.  Glycosylation of human pancreatic ribonuclease: differences between normal and tumor states. , 2003, Glycobiology.

[68]  U. Landegren,et al.  Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer , 2011, Proceedings of the National Academy of Sciences.

[69]  I. Powell.  Epidemiology and pathophysiology of prostate cancer in African-American men. , 2007, The Journal of urology.

[70]  C. Bertozzi,et al.  Cell surface glycoproteomic analysis of prostate cancer-derived PC-3 cells. , 2011, Bioorganic & medicinal chemistry letters.

[71]  J. Brooks,et al.  Increased expression of GCNT1 is associated with altered O‐glycosylation of PSA, PAP, and MUC1 in human prostate cancers , 2014, The Prostate.

[72]  T. Habuchi,et al.  Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. , 2014, Biochemical and biophysical research communications.

[73]  Pauline M Rudd,et al.  Glycans as cancer biomarkers. , 2012, Biochimica et biophysica acta.

[74]  P. Horák,et al.  TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth in vivo , 2014, Scientific Reports.

[75]  M. Emberton,et al.  Management of low risk prostate cancer—active surveillance and focal therapy , 2014, Nature Reviews Clinical Oncology.

[76]  B. Escudier,et al.  Who dies from prostate cancer? , 2014, Prostate Cancer and Prostatic Disease.

[77]  S. Brunak,et al.  Precision mapping of the human O‐GalNAc glycoproteome through SimpleCell technology , 2013, The EMBO journal.

[78]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[79]  T. Stamey,et al.  Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate , 1987 .

[80]  Peng Gao,et al.  Matrix assisted laser desorption ionization imaging mass spectrometry workflow for spatial profiling analysis of N-linked glycan expression in tissues. , 2013, Analytical chemistry.

[81]  O. J. Semmes,et al.  Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers* , 2006, Molecular & Cellular Proteomics.

[82]  Benjamin A. Neely,et al.  MALDI Imaging Mass Spectrometry Profiling of N-Glycans in Formalin-Fixed Paraffin Embedded Clinical Tissue Blocks and Tissue Microarrays , 2014, PloS one.

[83]  Barry J. Allen,et al.  MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate Cancer , 2005, Clinical & Experimental Metastasis.

[84]  L. Lebioda,et al.  Crystal structure of human prostatic acid phosphatase , 2000, The Prostate.

[85]  P. Lange,et al.  Sialyl-Lewis(x) and related carbohydrate antigens in the prostate. , 1995, Human pathology.

[86]  Yan Li,et al.  Simultaneous analysis of glycosylated and sialylated prostate-specific antigen revealing differential distribution of glycosylated prostate-specific antigen isoforms in prostate cancer tissues. , 2011, Analytical chemistry.

[87]  B. Benacerraf,et al.  Monoclonal antibodies to tissue-specific cell surface antigens. I. Characterization of an antibody to a prostate tissue antigen. , 1984, Clinical immunology and immunopathology.

[88]  K. Porvari,et al.  Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue , 2001, Cancer.

[89]  P. Robbins,et al.  Glycotyping of prostate specific antigen. , 2000, Glycobiology.

[90]  M. Tajiri,et al.  Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. , 2008, Glycobiology.

[91]  C. Bertozzi,et al.  Imaging the glycome , 2009, Proceedings of the National Academy of Sciences.

[92]  J. Siddiqui,et al.  Analysis of glycosyltransferase expression in metastatic prostate cancer cells capable of rolling activity on microvascular endothelial (E)-selectin. , 2008, Glycobiology.

[93]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[94]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[95]  Lai-Xi Wang,et al.  Enhanced immune recognition of cryptic glycan markers in human tumors. , 2009, Cancer research.

[96]  F. Magni,et al.  Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery , 2011, Proteomics.

[97]  S. Brosman,et al.  Gangliosides of organ-confined versus metastatic androgen-receptor-negative prostate cancer. , 2004, Biochemical and biophysical research communications.

[98]  S. Brosman,et al.  Endogenous immune response to gangliosides in patients with confined prostate cancer , 2005, International journal of cancer.

[99]  Mary Ann Comunale,et al.  Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. , 2009, Journal of proteome research.

[100]  J. Olsen,et al.  Immature truncated O-glycophenotype of cancer directly induces oncogenic features , 2014, Proceedings of the National Academy of Sciences.

[101]  Weihong Ding,et al.  Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy , 2011, Proteome Science.

[102]  W. Willett,et al.  Dietary Patterns and Risk of Prostate Cancer in U.S. Men , 2006, Cancer Epidemiology Biomarkers & Prevention.

[103]  J. Moul,et al.  Early prostate cancer: prevention, treatment modalities, and quality of life issues. , 2003, European urology.

[104]  Romas Na.  Prostatic acid phosphatase: current concepts. , 1983 .

[105]  Denong Wang.  N-glycan Cryptic Antigens as Active Immunological Targets in Prostate Cancer Patients , 2012, Journal of proteomics & bioinformatics.

[106]  Jing Chen,et al.  Glycoproteomic Analysis of Prostate Cancer Tissues by SWATH Mass Spectrometry Discovers N-acylethanolamine Acid Amidase and Protein Tyrosine Kinase 7 as Signatures for Tumor Aggressiveness , 2014, Molecular & Cellular Proteomics.

[107]  P. Conroy,et al.  Aberrant PSA glycosylation—a sweet predictor of prostate cancer , 2013, Nature Reviews Urology.

[108]  Y. Kaneda,et al.  Androgen-Regulated Transcriptional Control of Sialyltransferases in Prostate Cancer Cells , 2012, PloS one.

[109]  T. H. van der Kwast,et al.  Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. , 2013, Journal of the National Cancer Institute.

[110]  C. Piskorz,et al.  Biosynthesis of the carbohydrate antigenic determinants, Globo H, blood group H, and Lewis b: a role for prostate cancer cell alpha1,2-L-fucosyltransferase. , 2002, Glycobiology.

[111]  M. Dwek,et al.  A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[112]  N. Callewaert,et al.  Urinary prostate protein glycosylation profiling as a diagnostic biomarker for prostate cancer , 2015, The Prostate.

[113]  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005 .

[114]  M. Hollingsworth,et al.  Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. , 2010, Cancer research.

[115]  T. Irimura,et al.  Expression of sialylated MUC1 in prostate cancer: Relationship to clinical stage and prognosis , 2005, International journal of urology : official journal of the Japanese Urological Association.

[116]  Pauline M Rudd,et al.  Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. , 2003, Glycobiology.

[117]  T. Kislinger,et al.  The proteomics of prostate cancer exosomes , 2014, Expert review of proteomics.

[118]  K. Ohtsubo,et al.  Core fucose and bisecting GlcNAc, the direct modifiers of the N-glycan core: their functions and target proteins. , 2009, Carbohydrate research.

[119]  T. Kislinger,et al.  Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine. , 2012, Journal of proteome research.

[120]  P. Marker,et al.  fucosyltransferase1 and H-type complex carbohydrates modulate epithelial cell proliferation during prostatic branching morphogenesis. , 2001, Developmental biology.

[121]  D. Ornstein,et al.  The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma , 2009, The Prostate.

[122]  S. Kitahara,et al.  Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine-linked sugar-chain structures of prostatic acid phosphatase in human prostate carcinoma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[123]  N. Lumen,et al.  Glycosylation of prostate specific antigen and its potential diagnostic applications. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[124]  H. Danielsen,et al.  Up-regulation of the oligosaccharide sialyl LewisX: a new prognostic parameter in metastatic prostate cancer. , 1995, Cancer research.

[125]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[126]  Emanuel F Petricoin,et al.  Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy , 2010, Critical reviews in clinical laboratory sciences.

[127]  Benjamin A. Neely,et al.  Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling , 2013, Proteomics. Clinical applications.

[128]  Lisa H Cazares,et al.  Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.

[129]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.